Navigation Links
Genaera Corporation Announces Third Quarter Financial Results
Date:11/9/2007

PLYMOUTH MEETING, Pa., Nov. 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced its financial results for the three- and nine-month periods ended September 30, 2007. The net loss for the three-month period ended September 30, 2007, was $3.7 million, or $(0.21) per basic and diluted share, as compared to a net loss of $4.5 million, or $(0.26) per basic and diluted share, for the three-month period ended September 30, 2006. The net loss for the nine-month period ended September 30, 2007, was $9.9 million, or $(0.57) per basic and diluted share, as compared to a net loss of $17.6 million, or $(1.30) per basic and diluted share, for the nine- month period ended September 30, 2006.

Genaera's research and development expenses for the three- and nine-month periods ended September 30, 2007, were $2.9 million and $9.5 million, respectively, compared to $3.9 million and $14.6 million, respectively, for the same periods in 2006. The decrease was primarily due to a decrease in clinical and personnel costs as a result of the discontinuation of the EVIZON(TM) (squalamine lactate) program for the treatment of wet age-related macular degeneration, partially offset by an increase in clinical and personnel costs related to the trodusquemine (MSI-1436) program for the treatment of obesity.

Genaera's general and administrative expenses for the three- and nine- month periods ended September 30, 2007, were $1.2 million and $4.3 million, respectively, compared to $1.4 million and $4.5 million, respectively, for the same periods in 2006. The decrease in the three-month period ended September 30, 2007, was due principally to decreases in stock-based compensation expense for stock options and restricted s
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... agreement with Celula, Inc., a diagnostic testing company focused ... better patient care and improved outcomes.  Proceeds of the ... expand the commercialization of its products in the U.S. ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
(Date:4/30/2015)... 2015 SureClinical, a leader in cloud-based ... has joined SureClinical’s executive team as Chief Financial Officer. ... technology executive with over 25 years in leadership roles ... , Ms. Morris joins SureClinical from Marrone Bio Innovations ... CFO of MBI from its founding in 2006 until ...
(Date:4/29/2015)... April 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... 31, 2014. Biorem,s complete fiscal 2014 year-end financial statements and MD&A have ... , 2013 , 2014 , 2013 ... 19,596 Gross profit 1,326 , 1,703 , ... 1,493 , 3,377 , 4,562 Ebitda* 92 ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... October 22, 2007 In a major feat of ... laser with a wide-range of potential applications in chemistry, ... nanoantenna, the device is capable of resolving the chemical ... cell, with unprecedented detail. , Spearheaded by graduate students ...
... Dr. Cindy Dennison Haines has,been named Managing ... for health and medical professionals. "We,re delighted ... managing,Physician,s Briefing,s editing and writing team," said Editor-in-Chief,Barry ... and,HealthDay, a leading daily health news service for ...
... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ... that it has signed a definitive purchase,agreement to ... a purchase price of $5.6 million in cash ... restricted common stock. The purchase price is,subject to ...
Cached Biology Technology:Harvard University engineers demonstrate quantum cascade laser nanoantenna 2Cynthia Haines, M.D., Named Managing Editor of Physician's Briefing News Wire 2Orchid Cellmark to Purchase ReliaGene Technologies, Inc. 2Orchid Cellmark to Purchase ReliaGene Technologies, Inc. 3
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... to someone speak, we construct rich mental models that allow ... mental states and contexts. This ability to understand written or ... human mind and central to everyday social life. In a ... underlie discourse comprehension. The study appears in Brain ...
... Mo. Fish, unlike humans, can regenerate nerve connections and ... Now, University of Missouri researchers have discovered how the sea ... long nerve "highways" that link the brain to the spinal ... humans who have suffered spinal cord injuries. "There is ...
... have developed a bio-based solar cell. They embedded the ... are responsible of photosynthesis, into complex molecules developed in-house, ... Dr Wolfgang Schuhmann from the Department of Analytical Chemistry ... Matthias Rgner from the Department of Plant Biochemistry, the ...
Cached Biology News:Researchers map brain areas vital to understanding language 2MU research sheds light on nerve regeneration following spinal cord injury 2Bio-based solar cell 2